15,260 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,260 shares of the medical research company's stock, valued at approximately $1,040,000.

Other large investors have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in Exact Sciences during the 3rd quarter worth approximately $35,000. Vestor Capital LLC bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $46,000. V Square Quantitative Management LLC bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $47,000. Itau Unibanco Holding S.A. bought a new position in shares of Exact Sciences during the 2nd quarter worth approximately $29,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Exact Sciences by 92.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company's stock worth $49,000 after acquiring an additional 340 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Benchmark decreased their price target on shares of Exact Sciences from $67.00 to $65.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. BTIG Research decreased their price target on shares of Exact Sciences from $82.00 to $65.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Canaccord Genuity Group decreased their target price on shares of Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Evercore ISI decreased their target price on shares of Exact Sciences from $80.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein raised their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $74.47.

Exact Sciences Price Performance

Shares of NASDAQ EXAS traded down $0.15 during mid-day trading on Monday, reaching $51.33. The company had a trading volume of 3,566,730 shares, compared to its average volume of 2,618,678. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.98 and a current ratio of 2.12. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The firm has a market cap of $9.50 billion, a price-to-earnings ratio of -44.00 and a beta of 1.27. The business's 50-day simple moving average is $66.76 and its 200 day simple moving average is $56.46.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The business had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The company's revenue was up 12.8% compared to the same quarter last year. On average, research analysts predict that Exact Sciences Co. will post -1.02 earnings per share for the current fiscal year.

Insider Transactions at Exact Sciences

In other news, EVP Brian Baranick sold 929 shares of the business's stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the sale, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.36% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.